Log in

NASDAQ:SPPISpectrum Pharmaceuticals Stock Price, Forecast & News

$2.94
-0.03 (-1.01 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.81
Now: $2.94
$3.05
50-Day Range
$2.52
MA: $2.89
$3.30
52-Week Range
$1.74
Now: $2.94
$10.57
Volume1.32 million shs
Average Volume1.84 million shs
Market Capitalization$342.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Read More
Spectrum Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$1.32 per share

Profitability

Net Income$-112,690,000.00

Miscellaneous

Employees235
Market Cap$342.42 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

How has Spectrum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPPI stock has increased by 23.0% and is now trading at $2.94. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Spectrum Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spectrum Pharmaceuticals.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Spectrum Pharmaceuticals.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.01. View Spectrum Pharmaceuticals' earnings history.

What price target have analysts set for SPPI?

4 brokers have issued 1-year price objectives for Spectrum Pharmaceuticals' stock. Their forecasts range from $4.00 to $11.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $7.67 in the next year. This suggests a possible upside of 160.8% from the stock's current price. View analysts' price targets for Spectrum Pharmaceuticals.

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

Media stories about SPPI stock have been trending negative on Saturday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a news impact score of -2.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutSpectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Exelixis (EXEL), TG Therapeutics (TGTX), Verastem (VSTM), Bausch Health Companies (BHC), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), Opko Health (OPK) and AT&T (T).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.70%), State Street Corp (4.51%), Morgan Stanley (3.22%), Morgan Stanley (3.22%), Geode Capital Management LLC (1.37%) and Bank of New York Mellon Corp (1.02%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View institutional ownership trends for Spectrum Pharmaceuticals.

Which major investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, BlackRock Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., Arizona State Retirement System, Legal & General Group Plc, and Sargent Investment Group LLC. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Thomas J Riga, and William Ashton. View insider buying and selling activity for Spectrum Pharmaceuticals.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Alethea Capital Management LLC, Acadian Asset Management LLC, Two Sigma Investments LP, Two Sigma Advisers LP, State Street Corp, and Deutsche Bank AG. View insider buying and selling activity for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $2.94.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $342.42 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is www.sppirx.com.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.